AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · West Virginia

HB5588

Establish a regulated framework for the medical use of psilocybin to treat post-traumatic stress disorder (PTSD)

Status

Did not pass; died when the session ended

2026 Session

IntroducedFeb 16, 2026 (done)
PassedDid not happen (skipped)
SignedDid not happen (skipped)
Law in effectDid not happen (skipped)

Sponsor: Rick Hillenbrand (Republican)
Type: Therapeutic Access
Substances: Psilocybin

Official text

Summary (from PoliPsy)

The purpose of this bill is to adopt the Therapeutic Psilocybin Act.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: wvlegislature.gov

Legislative history

February 16, 2026
Referred
February 16, 2026
Referred
February 16, 2026
Introduced

Loading bill…